A novel high sensitivity ELISA for detection of antineutrophil cytoplasm antibodies against proteinase-3

Clinical and Experimental Rheumatology

Volumn 25, Issue 1 SUPPL. 44, 2007, Pages

  Hellmich, Bernhard ^a   Csernok, Elena ^a   Fredenhagen, Gert ^b   Gross, Wolfgang L ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b ORGenTec Diagnostika GmbH   (Germany)

Author keywords

ANCA; Churg Strauss syndrome; Diagnosis; ELISA assays; Microscopic polyangiitis; Systemic vasculitis; Wegener's granulomatosis

Indexed keywords

MYELOBLASTIN; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ROC CURVE; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; WEGENER GRANULOMATOSIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; AUTOANTIGENS; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; MALE; MIDDLE AGED; MYELOBLASTIN; PROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; WEGENER GRANULOMATOSIS;

EID: 34247536728     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. SAVIGE J, POLLOCK W, TREVISIN M: What do antineutrophil cytoplasmic antibodies tell us? Best Pract Res Clin Rheumatol 2005; 19: 263-76.
2. MUKHTYAR CB, FLOSSMANN O, LUQMANI RA: Clinical and biological assessment in systemic necrotizing vasculitides. Clin Exp Rheumatol 2006; 24 (Suppl. 41): S92-9.
3. SAVIGE J, DIMECH W, FRITZLER M et al.: Addendum to the International Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies. Quality control guidelines, comments, and recommendations for testing in other autoimmune diseases. Am J Clin Pathol 2003; 120: 312-8.
4. WANG G, CSERNOK E, de GROOT K, GROSS WL: Comparison of eight commercial kits for quantitation of antineutrophil cytoplasmic antibodies (ANCA). J Immunol Methods 1997; 208: 203-11.
5. HOLLE JU, HELLMICH B, BACKES M, GROSS WL, CSERNOK E: Variations in performance characteristics of commercial enzyme immunoassay kits for the detection of antineutrophil cytoplasmatic antibodies: What is the optimal cut-off? Ann Rheum Dis 2005; 64: 1773-9.
6. CSERNOK E, HOLLE J, HELLMICH B et al.: Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies against proteinase-3 in Wegener's granulomatosis: First results from a multicenter study. Rheumatology 2004; 43: 174-80.
7. LEE AS, FINKIELMAN JD, PEIKERT T, HUMMEL AM, VISS MA, SPECKS U: A novel capture-ELISA for detection of anti-neutrophil cytoplasmic antibodies (ANCA) based on c-myc peptide recognition in carboxy-terminally tagged recombinant neutrophil serine proteases. J Immunol Methods 2005; 307: 62-72. Epub 2005 Oct 3.
8. JENNETTE J, ANDRASSY K, BACON PA et al.: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-92.
9. LEAVITT R, FAUCI A, BLOCH D et al.: The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990; 33: 1101-7.
10. JAYNE DR, RASMUSSEN N: Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin Proc 1997; 72: 737-47.
11. REINHOLD-KELLER E, BEUGE N, LATZA U et al.: An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000; 43: 1021-32.
12. de GROOT K, GROSS W, HERLYN K, REINHOLD-KELLER E: Development and validation of a disease extent index for Wegener's granulomatosis. Clin Nephrol 2001; 55: 31-8.
13. CSERNOK E, AHLQUIST D, ULLRICH S, GROSS WL: A critical evaluation of commercial immunoassays for antineutrophil cytoplasmic antibodies directed against proteinase 3 and myeloperoxidase in Wegener's granulomatosis and microscopic polyangiitis. Rheumatology (Oxford) 2002; 41: 1313-7.
14. HANLEY J, McNEIL B: The meaning and use of the area under a receiver operating characteristics (ROC) curve. Radiology 1982; 143: 29-36.
15. VOSWINKEL J, MUELLER A, KRAEMER JA et al.: B lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions. Ann Rheum Dis 2006; 65: 859-64. Epub 2005 Nov 16.
16. VOSWINKEL J, MULLER A, LAMPRECHT P: Is PR3-ANCA formation initiated in Wegener's granulomatosis lesions? Granulomas as potential lymphoid tissue maintaining autoantibody production. Ann N Y Acad Sci 2005; 1051: 12-9.